Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase I/II Clinical Trial of the mTor Inhibitor RAD001 (Everolimus) in Combination With Lenalidomide (Revlimid) for Patients With Relapsed or Refractory Lymphoid Malignancy

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT01075321
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-28T10:37:58.585229+00:00
Published At
2020-03-23T00:00:00+00:00
Record Updated At
2020-10-22
Results Posted At
2020-03-23
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Adult Nasal Type Extranodal NK/T-cell Lymphoma", "Anaplastic Large Cell Lymphoma", "Angioimmunoblastic T-cell Lymphoma", "Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue", "Hepatosplenic T-cell Lymphoma", "Nodal Marginal Zone B-cell Lymphoma", "Peripheral T-cell Lymphoma", "Post-transplant Lymphoproliferative Disorder", "Recurrent Adult Burkitt Lymphoma", "Recurrent Adult Diffuse Large Cell Lymphoma", "Recurrent Adult Hodgkin Lymphoma", "Recurrent Adult T-cell Leukemia/Lymphoma", "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Grade 3 Follicular Lymphoma", "Recurrent Mantle Cell Lymphoma", "Recurrent Mycosis Fungoides/Sezary Syndrome", "Splenic Marginal Zone Lymphoma", "Waldenstrom Macroglobulinemia"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2020-10-22"
protocolSection.identificationModule.nctId
"NCT01075321"
protocolSection.identificationModule.officialTitle
"A Phase I/II Clinical Trial of the mTor Inhibitor RAD001 (Everolimus) in Combination With Lenalidomide (Revlimid) for Patients With Relapsed or Refractory Lymphoid Malignancy"
protocolSection.statusModule.overallStatus
"COMPLETED"
protocolSection.designModule.phases
["PHASE1", "PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
"2020-03-23"

Study condition terms

  • Adult Nasal Type Extranodal NK/T-cell Lymphoma (protocolSection.conditionsModule.conditions)
  • Anaplastic Large Cell Lymphoma (protocolSection.conditionsModule.conditions)
  • Angioimmunoblastic T-cell Lymphoma (protocolSection.conditionsModule.conditions)
  • Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue (protocolSection.conditionsModule.conditions)
  • Hepatosplenic T-cell Lymphoma (protocolSection.conditionsModule.conditions)
  • Nodal Marginal Zone B-cell Lymphoma (protocolSection.conditionsModule.conditions)
  • Peripheral T-cell Lymphoma (protocolSection.conditionsModule.conditions)
  • Post-transplant Lymphoproliferative Disorder (protocolSection.conditionsModule.conditions)
  • Recurrent Adult Burkitt Lymphoma (protocolSection.conditionsModule.conditions)
  • Recurrent Adult Diffuse Large Cell Lymphoma (protocolSection.conditionsModule.conditions)
  • Recurrent Adult Hodgkin Lymphoma (protocolSection.conditionsModule.conditions)
  • Recurrent Adult T-cell Leukemia/Lymphoma (protocolSection.conditionsModule.conditions)
  • Recurrent Grade 1 Follicular Lymphoma (protocolSection.conditionsModule.conditions)
  • Recurrent Grade 2 Follicular Lymphoma (protocolSection.conditionsModule.conditions)
  • Recurrent Grade 3 Follicular Lymphoma (protocolSection.conditionsModule.conditions)
  • Recurrent Mantle Cell Lymphoma (protocolSection.conditionsModule.conditions)
  • Recurrent Mycosis Fungoides/Sezary Syndrome (protocolSection.conditionsModule.conditions)
  • Splenic Marginal Zone Lymphoma (protocolSection.conditionsModule.conditions)
  • Waldenstrom Macroglobulinemia (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.